{
  "docId": "019de073-a45e-764e-97a1-b4793295a3f1",
  "docSlug": "90578b12d3108983c23425e7ddd95d83",
  "documentTitle": "ATAI | Investor Presentation Deck | 41 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 41,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-a45e-764e-97a1-b4793295a3f1/19",
  "deckHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1",
  "deckJsonHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1.json",
  "deckAnchorHref": "/decks/019de073-a45e-764e-97a1-b4793295a3f1#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.26
      },
      "kind": "image",
      "text": "Chemical structure of COMP360",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78748f31-7fc3-461e-ba65-4e7e0f0ccf6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.48,
        "y": 0.28
      },
      "kind": "list",
      "text": "LAST YEAR: Phase 2b trial completed (n = 233) - Positive topline results",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "650f9db0-086a-426e-ab9e-e1530ab09e83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.48,
        "y": 0.52
      },
      "kind": "list",
      "text": "THIS YEAR: Phase 3 program design announced - First Phase 3 to start this quarter - Topline data expected by end of 2024 and mid-2025",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fef3252d-f77d-4cd8-8e74-6cb62b214851",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.39,
        "x": 0.08,
        "y": 0.7
      },
      "kind": "paragraph",
      "text": "Compass' lead asset is COMP360, a proprietary formulation of synthetic psilocybin",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "984b9b15-c168-4839-9747-ae20a0b8e387",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Latest developments at COMPASS Pathways include positive topline results from phase 2 and announcement of phase 3 program design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbed5e9c-cbaa-49de-88e6-0a868a6006cc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 41,
      "from": 6,
      "beatId": "54d980bb-d331-41ca-8841-b0eb7beb049c",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation provides a solution by showcasing ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 40,
      "from": 10,
      "beatId": "4c06d6d1-b3e1-4c1e-bceb-806b8f57a880",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The presentation provides evidence and proof of the effectiveness of ATAI Life Sciences' treatments through various studies and data.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 10,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "5cd92045-52c0-4b53-b15d-4dd6b345ff72",
      "evidence": "The presentation showcases ATAI Life Sciences' pipeline and progress in developing treatments for mental health disorders.",
      "position": 1,
      "objective": "How can we effectively treat mental health disorders?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.7,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}